Cancer Therapeutics (CT) Program

The overarching goals of the Cancer Therapeutics (CT) program are to advance the translation of ideas through:
1) the development and translation of new therapeutic agents; 2) biotechnology approaches (i.e., new therapies or drug-delivery vehicles, innovative imaging technologies, and data analysis systems) to enhance new cancer treatments and diagnostics; and 3) to develop and initiate innovative clinical trials with focus on priority cancers.

The thematic areas and specific aims of the CT Program are:

1. Drug Development and Delivery: To foster the development and translation of new therapeutic agents.
2. Biotechnology: To utilize biotechnology to develop new cancer treatments and diagnostics.
3. Developmental Therapeutics: To develop and initiate innovative clinical trials with a focus on priority cancers.

• Kathleen Moore, MD Program Co-Leader
• Lacey McNally, PhD Program Co-Leader

VIEW PROGRAM MEMBERS